Bellecapital International Ltd. Increases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Bellecapital International Ltd. lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 44.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,600 shares of the biopharmaceutical company’s stock after acquiring an additional 6,002 shares during the period. Regeneron Pharmaceuticals accounts for about 2.5% of Bellecapital International Ltd.’s investment portfolio, making the stock its 15th largest position. Bellecapital International Ltd.’s holdings in Regeneron Pharmaceuticals were worth $13,962,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of REGN. Focus Financial Network Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 7.4% during the 3rd quarter. Focus Financial Network Inc. now owns 538 shares of the biopharmaceutical company’s stock worth $566,000 after acquiring an additional 37 shares during the period. Americana Partners LLC purchased a new position in Regeneron Pharmaceuticals in the third quarter valued at approximately $330,000. Farther Finance Advisors LLC raised its holdings in Regeneron Pharmaceuticals by 7.9% in the third quarter. Farther Finance Advisors LLC now owns 724 shares of the biopharmaceutical company’s stock valued at $761,000 after buying an additional 53 shares during the period. Empire Life Investments Inc. purchased a new position in Regeneron Pharmaceuticals in the third quarter valued at approximately $5,030,000. Finally, Van ECK Associates Corp raised its holdings in Regeneron Pharmaceuticals by 8.9% in the third quarter. Van ECK Associates Corp now owns 58,136 shares of the biopharmaceutical company’s stock valued at $61,115,000 after buying an additional 4,742 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $698.74 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The company has a market cap of $76.39 billion, a PE ratio of 18.25, a P/E/G ratio of 2.34 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 12 month low of $642.00 and a 12 month high of $1,211.20. The company has a fifty day moving average price of $698.51 and a two-hundred day moving average price of $868.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the business posted $11.86 earnings per share. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.50%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Bernstein Bank cut their price target on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. TD Cowen cut their price target on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Wolfe Research initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price objective for the company. Finally, Oppenheimer lowered their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.